Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Mocci G, Tursi A, Maconi G, Cataletti G, Mantia B, Serio M, Scarcelli A, Pagnini C, Graziani MG, Di Paolo MC, Pranzo G, Luppino I, Paese P, Elisei W, Monterubbianesi R, Faggiani R, Ferronato A, Perini B, Savarino E, Onidi FM, Binaghi L, Usai Satta P, Schiavoni E, Napolitano D, Scaldaferri F, Pugliese D, Pica R, Cocco A, Zippi M, Rodino S, Sebkova L, Rocco G, Sacchi C, Zampaletta C, Gaiani F, De Angelis G, Kayali S, Fanigliulo L, Lorenzetti R, Allegretta L, Scorza S, Cuomo A, Donnarumma L, Della Valle N, Sacco R, Forti G, Antonelli E, Bassotti G, Iannelli C, Luzza F, Aragona G, Perazzo P, Lauria A, Piergallini S, Colucci R, Bianco MA, Meucci C, Giorgetti G, Clemente V, Fiorella S, Penna A, De Medici A, Picchio M, Papa A. Mocci G, et al. Among authors: scaldaferri f. Expert Opin Biol Ther. 2023 Mar;23(3):293-304. doi: 10.1080/14712598.2023.2185510. Epub 2023 Mar 2. Expert Opin Biol Ther. 2023. PMID: 36843568
Extraintestinal manifestations in inflammatory bowel disease.
Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A. Danese S, et al. Among authors: scaldaferri f. World J Gastroenterol. 2005 Dec 14;11(46):7227-36. doi: 10.3748/wjg.v11.i46.7227. World J Gastroenterol. 2005. PMID: 16437620 Free PMC article. Review.
New therapeutic approach in inflammatory bowel disease.
Papa A, Mocci G, Scaldaferri F, Bonizzi M, Felice C, Andrisani G, Gasbarrini A. Papa A, et al. Among authors: scaldaferri f. Eur Rev Med Pharmacol Sci. 2009 Mar;13 Suppl 1:33-5. Eur Rev Med Pharmacol Sci. 2009. PMID: 19530509 Review.
Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders.
Lopetuso LR, Petito V, Graziani C, Schiavoni E, Paroni Sterbini F, Poscia A, Gaetani E, Franceschi F, Cammarota G, Sanguinetti M, Masucci L, Scaldaferri F, Gasbarrini A. Lopetuso LR, et al. Among authors: scaldaferri f. Dig Dis. 2018;36(1):56-65. doi: 10.1159/000477205. Epub 2017 Jul 7. Dig Dis. 2018. PMID: 28683448
Can We Predict the Efficacy of Anti-TNF-α Agents?
Lopetuso LR, Gerardi V, Papa V, Scaldaferri F, Rapaccini GL, Gasbarrini A, Papa A. Lopetuso LR, et al. Among authors: scaldaferri f. Int J Mol Sci. 2017 Sep 14;18(9):1973. doi: 10.3390/ijms18091973. Int J Mol Sci. 2017. PMID: 28906475 Free PMC article. Review.
248 results